Minimally Invasive Biopsy Techniques Market to Grow at 10.22% CAGR through 2029
The demand for
non-invasive treatment procedures and increasing incidence of cancer is
expected to drive the Global Minimally Invasive Biopsy Techniques Market growth
in the forecast period, 2025-2029.
According to
TechSci Research report, “Minimally Invasive Biopsy Techniques Market – Global
Industry Size, Share, Trends, Competition Forecast & Opportunities, 2019-2029F”,
the Global Minimally Invasive Biopsy
Techniques Market stood at USD 12.47 Billion in 2023 and is anticipated to
project steady growth in the forecast period with a CAGR of 10.22% through 2029.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global Minimally Invasive Biopsy Techniques Market”
The expansion of
the Global Minimally Invasive Biopsy Techniques Market is being propelled by
several key drivers, signifying a substantial transformation in diagnostic
methodologies. A primary catalyst for this growth is the escalating global
incidence of cancer and chronic diseases, necessitating the adoption of more
precise and less invasive diagnostic methods. This surge in demand underscores
the indispensable role played by minimally invasive biopsy techniques, which
offer patients and healthcare providers a safer and more efficient means of
diagnosis compared to conventional methods.
The relentless
pace of technological advancements is a significant catalyst driving the
expansion of the market for minimally invasive biopsy techniques. Particularly
noteworthy are the strides made in imaging modalities and biopsy instruments,
which have ushered in a new era in diagnostic procedures. These innovations
have brought about a fundamental transformation in the landscape of minimally
invasive biopsy techniques, substantially augmenting their precision and
efficacy.
These
advancements have not gone unnoticed, garnering considerable interest and
adoption among both healthcare professionals and patients. Healthcare providers
are increasingly turning to these advanced techniques, recognizing their
potential to revolutionize diagnostic practices and improve patient outcomes.
Patients, too, are becoming more receptive to minimally invasive biopsy
procedures, drawn by the promise of reduced discomfort and quicker recovery
times compared to traditional methods.
As these
technological innovations continue to evolve and become more refined, the
market for minimally invasive biopsy techniques is expected to experience
further growth and expansion. With ongoing advancements paving the way for even
greater precision and efficiency, the future of minimally invasive biopsy
procedures looks promising, offering new possibilities for enhanced diagnosis
and treatment in healthcare settings worldwide.
Furthermore,
there has been a discernible increase in awareness among both patients and
healthcare professionals regarding the myriad benefits of minimally invasive
procedures. As understanding of these techniques deepens, their adoption rates
continue to climb, further driving market growth. Additionally, supportive
government initiatives aimed at promoting minimally invasive diagnostic
procedures, coupled with ongoing enhancements in healthcare infrastructure, are
playing pivotal roles in propelling the overall development of the market.
These factors
paint a promising trajectory for the Global Minimally Invasive Biopsy
Techniques Market, teeming with opportunities for further growth and
innovation. As technology continues to advance and awareness spreads, the
market is poised for sustained expansion. The overarching objective remains
steadfastly focused on delivering safer, more efficient, and more accessible
diagnostic solutions to patients worldwide, thereby ensuring improved outcomes
and heightened quality of care on a global scale.
The Global Minimally
Invasive Biopsy Techniques Market is segmented into product offered, technique,
circulating biomarker, application, end user, regional distribution, and
company
Based on circulating
biomarker, in the global minimally invasive biopsy techniques market,
Circulating Tumor DNA (ctDNA) is emerging as a dominant player. CtDNA, also
known as cell-free tumor DNA, is genetic material shed by tumor cells into the
bloodstream. Its dominance stems from its potential to provide valuable
insights into a patient's cancer profile through a simple blood draw, thereby
enabling non-invasive and real-time monitoring of tumor dynamics. CtDNA
analysis offers clinicians a minimally invasive means of assessing tumor
mutational status, detecting minimal residual disease, monitoring treatment
response, and predicting disease progression. These attributes make ctDNA a
preferred biomarker for liquid biopsy-based diagnostic approaches, driving its
prominence in the global Minimally Invasive Biopsy Techniques Market.
Given its
multifaceted utility and non-invasive nature, ctDNA has emerged as the
preferred biomarker for liquid biopsy-based diagnostic approaches. Its
prominence in the global Minimally Invasive Biopsy Techniques Market is driven
by the increasing recognition of its clinical utility and the growing demand
for minimally invasive diagnostic solutions. As the field continues to advance
and technologies evolve, ctDNA is poised to remain a cornerstone of liquid
biopsy-based diagnostics, driving innovation and shaping the future of cancer
care.
Based on region,
North America leads the global Minimally Invasive Biopsy Techniques Market due
to several key factors. Its advanced healthcare infrastructure, equipped with
state-of-the-art facilities, enables precise biopsy procedures. The region's
commitment to technological innovation fosters the development and adoption of
groundbreaking techniques. Favorable reimbursement policies ensure widespread
access to these advanced technologies, driving market growth. Additionally,
North America's robust research and development landscape, involving academic
institutions and key market players, continuously evolves and refines minimally
invasive biopsy technologies, further solidifying its leadership position in
the global market.
Major companies
operating in Global Minimally Invasive Biopsy Techniques Market are:
- F. Hoffmann-La
Roche AG
- Thermo Fisher
Scientific, Inc.
- PerkinElmer
Inc.
- QIAGEN NV
- Guardant
Health, Inc.
- Veracyte, Inc.
- Myriad
Genetics, Inc.
- Biocept, Inc.
- NeoGenomics
Laboratories, Inc.
- Adaptive
Biotechnologies Corporation
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The minimally
invasive biopsy techniques use real-time analysis of tumor-derived material
extracted from various body fluids, which is a promising tool that could enhance
the current practice by assisting clinicians in disease screening, satisfying
patients' needs for the best treatment, and monitoring treatment response and
resistance mechanisms. Besides, cancer has significant potential for the future
Application of artificial intelligence (AI) in medicine, not only for early and
accurate diagnosis but also treatment, therapy, and illness prognosis
prediction. Rapidly developing minimally invasive techniques hold considerable
promise for the efficient, risk-free treatment of benign breast lesions. The
expense of surgical treatments requiring general anesthesia is reduced by the
fact that percutaneous treatment of breast tumors is typically carried out in
an office setting under local anesthetic. The utilization of minimally invasive
techniques for biopsy is expected to show promising growth in the future period
with more technological advancement and is expected to become the most
preferred way for biopsy, globally.,” said Mr. Karan Chechi, Research Director
with TechSci Research, a research-based management consulting firm.
“Minimally Invasive Biopsy Techniques Market - Global
Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Offered
(Tests, Kits & Consumables, Instruments), By Technique (Liquid Biopsy,
Optical Biopsy, Brush Biopsy, Pigmented Lesion Assays, Others {Breath Biopsy
etc.}), By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free DNA
(cfDNA), Circulating Tumor DNA (ctDNA), Extracellular Vesicles, Others {miRNA,
CTECs, circRNA etc.}), By Application (Clinical and Therapeutic), By End User
(Hospitals & Clinics, Ambulatory Care Center, Academic & Research
Institutions), By Region and Competition, 2019-2029F”,
has evaluated the future growth potential of Global Minimally Invasive Biopsy
Techniques Market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Minimally Invasive
Biopsy Techniques Market.
Contact
TechSci Research
LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com